Eli Lilly’s weight loss drugs have delivered blockbuster sales in recent quarters. The company is a leader in this market ...

Discover why Eli Lilly's stock downturn may present new opportunities. Learn about valuation, Zepbound pricing, and 2026 ...

Wall Street's major averages ended lower on Friday, with the S&P 500 (SP500) and the Nasdaq (COMP:IND) ending the week in the ...

Eli Lilly's innovation and pipeline diversification support long-term growth, despite patent risks and competition. Read more ...

Eli Lilly is investing $6B in a Huntsville, Ala., plant to make weight-loss and other medicines. Here’s what we know about ...

Dec 10 (Reuters) - French biotech company Abivax's shares rose by over 20% on Wednesday on market rumours that U.S. pharma ...

Dec 9 (Reuters) - Eli Lilly said on Tuesday it will invest more than $6 billion in a new active drug ingredient manufacturing ...

The pharmaceutical stock can still deliver.

The maker of Zepbound reported results from a study of retatrutide, which targets three hormones in the body and led to much more weight loss than any approved drug.

Eli Lilly and Company (NYSE:LLY) is one of the best pharma stocks to invest in. On December 7, Eli Lilly and Company ...

Dr. Stacy L. Smith, founder of the USC Annenberg Inclusion Initiative and longtime thought parter of TheWrap, was honored ...

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.